학술논문

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Document Type
Article
Source
Investigational New Drugs; Apr2024, Vol. 42 Issue 2, p179-184, 6p
Subject
THERAPEUTIC use of antineoplastic agents
THERAPEUTIC use of monoclonal antibodies
PATIENT safety
MACROPHAGES
RESEARCH funding
CLINICAL trials
IMMUNOTHERAPY
FATIGUE (Physiology)
ANTINEOPLASTIC agents
DESCRIPTIVE statistics
FEVER
METASTASIS
MONOCLONAL antibodies
GENE expression
RENAL cell carcinoma
COMPARATIVE studies
DRUG tolerance
IMMUNOSUPPRESSION
NAUSEA
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)